To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. VWR will not lift restrictions for residential shipping addresses.
Spécifications
- Size:1 Kit
- Cat. no.:89156-518
- No. of Assays/Kit:96 - 192 assays
- Supplier No.:AK531-0001
Spécifications
A propos de cet article
The HDAC3/NCOR1 Fluorescent Activity Assay/Drug Discovery Kit is a complete assay system designed to measure the lysyl deacetylase activity of the recombinant human HDAC3 included in the kit. The kit is ideal for chemical library screening for candidate inhibitors or activators or kinetic assay of the enzyme under varying conditions.
The preparation provided with this kit, a complex of HDAC3 with the NCOR1 Deacetylase Activation Domain (DAD), has over 100-fold greater specific activity than recombinant HDAC3 alone and more closely approximates the fully active in vivo form of the enzyme.The complex for drug discovery purposes is the possibility of identifying small molecule disruptors of the HDAC3-DAD interaction
The Fluor de Lys® HDAC3/NCOR1 assay is based on the Fluor de Lys® Substrate and Fluor de Lys® Developer combination. The assay procedure has two steps. First, the Fluor de Lys® SIRT1 Substrate, which comprises an acetylated lysine side chain, is incubated with HDAC3/NCOR1. Deacetylation of the substrate sensitizes the substrate so that, in the second step, treatment with the Fluor de Lys®Developer II produces a fluorophore.
In addition to active site binding, there is another potential route to inhibition, one more likely to be highly specific to HDAC3.